- In Joint Action 2, EUnetHTA will continue to address methodological challenges of HTA.
- In Joint Action 1 (2010-2012) EUnetHTA has produced nine guidelines on methodological issues associated with relative effectiveness assessment of pharmaceuticals (REA) (1).
- In Joint Action 2 (2012-2015) EUnetHTA is continuing to address methodological challenges of HTA currently taking up a topic of economic evaluation.
This effort includes both systematic review of the literature already available, original input from the researchers of several European countries involved in the EUnetHTA methodological activities (2), and stakeholder and public consultations on the draft versions of the documents.
The process and the results – intermediate and final – of EUnetHTA’s effort in this field are publicly available to monitor and assess. Any interaction with other projects/initiatives in methodological research in HTA is reflected in the EUnetHTA documentation (e.g. EUnetHTA has no association with the process or results of the ECHoutcome project).
https://www.eunethta.eu/outputs/eunethta-joint-action-2010-12/methodological-guideline-for-rea-of-pharmaceuticals-clinical-endpoints/
https://www.eunethta.eu/activities/EUnetHTA%20Joint%20Action%202%20%282012-15%29/ja2-wp7-methodology-development-and-evidence-generation